PURPOSE: To investigate the expression of human beta-defensins (hBDs) by human corneal epithelium and determine the effects of proinflammatory cytokines on expression of human beta-defensin (hBD)-2 by human corneal epithelial cells (HCECs) in culture. METHODS: RNA was extracted from corneal epithelial cells scraped from cadaveric corneas and from cultured HCECs, and RT-PCR was performed to detect hBD-1, -2, and -3 mRNA. To study the effects of proinflammatory cytokines on expression of defensin, HCECs were cultured and then exposed to interleukin (IL)-1beta or tumor necrosis factor (TNF)-alpha for up to 36 hours, with a range of concentrations (0.01-100 ng/mL). In some experiments, cells were pretreated with various cell signaling pathway inhibitors before the addition of IL-1beta. At the end of the incubations, the cells were harvested for RT-PCR and the culture media collected for the detection by immunoblot analysis of secreted defensin peptide. RESULTS: All epithelial tissue collected from cadaveric corneas expressed mRNA for hBD-1. hBD-2 was detectable in two of eight donors corneas, whereas hBD-3 was detected in five. All primary cultures of HCECs expressed hBD-1 and -3. A faint band for hBD-2 was detectable in three of eight cultures. Cultures of simian virus (SV)40-transformed HCECs always expressed hBD-1 and -3, but did not express hBD-2 under control conditions. IL-1beta and TNFalpha each stimulated the expression of hBD-2 in HCECs and were more effective in combination than alone. The effects of IL-1beta were concentration- (maximal at 10 ng/mL) and time-dependent (maximal at 12 hours and 24 hours for hBD-2 mRNA expression and protein secretion, respectively). The upregulation of hBD-2 mRNA persisted for at least 24 hours after removal of IL-1beta. The NFkappaB inhibitors pyrrolidinedithiocarbamate (PDTC; 100 microM), caffeic acid phenethyl ester (CAPE; 90 microM), and MG-132 (25 microM), blocked IL-1beta-stimulated expression of hBD-2. The p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (5 microM) and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (25 microM) partially blocked (by 47% and 59%, respectively) the effect of IL-1beta. However, PD98059, an ERK inhibitor, had no effect. Genistein (50 microM) and dexamethasone (1 microM) also partially blocked (by 26% and 28%, respectively) the effect of IL-1beta. CONCLUSIONS: Human corneal epithelium expresses hBD-1 and -3. hBD-2 is not typically present, but its expression can be stimulated by proinflammatory cytokines such as IL-1beta, acting through mitogen-activated protein (MAP) kinase and nuclear factor (NF)-kappaB pathways. Because IL-1 is known to be increased at the ocular surface after injury, the current observations provide a mechanism to explain the previous finding that hBD-2 is upregulated in regenerating corneal epithelium. Cytokine stimulation of hBD-2 expression most likely provides additional protection against infection and raises the possibility that this defensin in particular may be involved in the wound-healing response, per se.
PURPOSE: To investigate the expression of human beta-defensins (hBDs) by human corneal epithelium and determine the effects of proinflammatory cytokines on expression of humanbeta-defensin (hBD)-2 by human corneal epithelial cells (HCECs) in culture. METHODS: RNA was extracted from corneal epithelial cells scraped from cadaveric corneas and from cultured HCECs, and RT-PCR was performed to detect hBD-1, -2, and -3 mRNA. To study the effects of proinflammatory cytokines on expression of defensin, HCECs were cultured and then exposed to interleukin (IL)-1beta or tumor necrosis factor (TNF)-alpha for up to 36 hours, with a range of concentrations (0.01-100 ng/mL). In some experiments, cells were pretreated with various cell signaling pathway inhibitors before the addition of IL-1beta. At the end of the incubations, the cells were harvested for RT-PCR and the culture media collected for the detection by immunoblot analysis of secreted defensin peptide. RESULTS: All epithelial tissue collected from cadaveric corneas expressed mRNA for hBD-1. hBD-2 was detectable in two of eight donors corneas, whereas hBD-3 was detected in five. All primary cultures of HCECs expressed hBD-1 and -3. A faint band for hBD-2 was detectable in three of eight cultures. Cultures of simian virus (SV)40-transformed HCECs always expressed hBD-1 and -3, but did not express hBD-2 under control conditions. IL-1beta and TNFalpha each stimulated the expression of hBD-2 in HCECs and were more effective in combination than alone. The effects of IL-1beta were concentration- (maximal at 10 ng/mL) and time-dependent (maximal at 12 hours and 24 hours for hBD-2 mRNA expression and protein secretion, respectively). The upregulation of hBD-2 mRNA persisted for at least 24 hours after removal of IL-1beta. The NFkappaB inhibitors pyrrolidinedithiocarbamate (PDTC; 100 microM), caffeic acid phenethyl ester (CAPE; 90 microM), and MG-132 (25 microM), blocked IL-1beta-stimulated expression of hBD-2. The p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (5 microM) and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (25 microM) partially blocked (by 47% and 59%, respectively) the effect of IL-1beta. However, PD98059, an ERK inhibitor, had no effect. Genistein (50 microM) and dexamethasone (1 microM) also partially blocked (by 26% and 28%, respectively) the effect of IL-1beta. CONCLUSIONS:Human corneal epithelium expresses hBD-1 and -3. hBD-2 is not typically present, but its expression can be stimulated by proinflammatory cytokines such as IL-1beta, acting through mitogen-activated protein (MAP) kinase and nuclear factor (NF)-kappaB pathways. Because IL-1 is known to be increased at the ocular surface after injury, the current observations provide a mechanism to explain the previous finding that hBD-2 is upregulated in regenerating corneal epithelium. Cytokine stimulation of hBD-2 expression most likely provides additional protection against infection and raises the possibility that this defensin in particular may be involved in the wound-healing response, per se.
Authors: J R García; A Krause; S Schulz; F J Rodríguez-Jiménez; E Klüver; K Adermann; U Forssmann; A Frimpong-Boateng; R Bals; W G Forssmann Journal: FASEB J Date: 2001-08 Impact factor: 5.191
Authors: L A Duits; M Rademaker; B Ravensbergen; M A van Sterkenburg; E van Strijen; P S Hiemstra; P H Nibbering Journal: Biochem Biophys Res Commun Date: 2001-01-19 Impact factor: 3.575
Authors: A Wada; K Ogushi; T Kimura; H Hojo; N Mori; S Suzuki; A Kumatori; M Se; Y Nakahara; M Nakamura; J Moss; T Hirayama Journal: Cell Microbiol Date: 2001-02 Impact factor: 3.715
Authors: P I Song; T A Abraham; Y Park; A S Zivony; B Harten; H F Edelhauser; S L Ward; C A Armstrong; J C Ansel Journal: Invest Ophthalmol Vis Sci Date: 2001-11 Impact factor: 4.799
Authors: T Birchler; R Seibl; K Büchner; S Loeliger; R Seger; J P Hossle; A Aguzzi; R P Lauener Journal: Eur J Immunol Date: 2001-11 Impact factor: 5.532
Authors: K Ogushi ; A Wada; T Niidome; N Mori; K Oishi; T Nagatake; A Takahashi; H Asakura; S Makino ; H Hojo; Y Nakahara; M Ohsaki; T Hatakeyama; H Aoyagi; H Kurazono; J Moss; T Hirayama Journal: J Biol Chem Date: 2001-05-31 Impact factor: 5.157
Authors: J R García; F Jaumann; S Schulz; A Krause; J Rodríguez-Jiménez; U Forssmann; K Adermann; E Klüver; C Vogelmeier; D Becker; R Hedrich; W G Forssmann; R Bals Journal: Cell Tissue Res Date: 2001-11 Impact factor: 5.249
Authors: Aaron B Sullivan; K P Connie Tam; Matteo M E Metruccio; David J Evans; Suzanne M J Fleiszig Journal: Infect Immun Date: 2015-02-09 Impact factor: 3.441
Authors: S Rodríguez-Martínez; M E Cancino-Díaz; L Jiménez-Zamudio; E García-Latorre; J C Cancino-Díaz Journal: Br J Ophthalmol Date: 2005-07 Impact factor: 4.638
Authors: Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott Journal: Ocul Surf Date: 2013-01-29 Impact factor: 5.033